دورية أكاديمية
Impact of COVID-19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial
| العنوان: | Impact of COVID-19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial |
|---|---|
| المؤلفون: | Bhatt, Ankeet S., Kosiborod, Mikhail N., Claggett, Brian L., Miao, Zi Michael, Vaduganathan, Muthiah, Lam, Carolyn S.P., Hernandez, Adrian F., Martinez, Felipe A., Inzucchi, Silvio E., Shah, Sanjiv J., de Boer, Rudolf A., Jhund, Pardeep S., Desai, Akshay S., Fang, James C., Han, Yaling, Comin-Colet, Josep, Drożdż, Jarosław, Vardeny, Orly, Merkely, Bela, Lindholm, Daniel, Peterson, Magnus, Langkilde, Anna Maria, McMurray, John J.V., Solomon, Scott D. |
| المصدر: | Bhatt , A S , Kosiborod , M N , Claggett , B L , Miao , Z M , Vaduganathan , M , Lam , C S P , Hernandez , A F , Martinez , F A , Inzucchi , S E , Shah , S J , de Boer , R A , Jhund , P S , Desai , A S , Fang , J C , Han , Y , Comin-Colet , J , Drożdż , J , Vardeny , O , Merkely , B , Lindholm , D , Peterson , M , .... |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being, name=SDG 3 - Good Health and Well-being |
| الوصف: | Aim: COVID-19 may affect clinical risk in patients with heart failure. DELIVER began before and was conducted during the COVID-19 pandemic. This study aimed to evaluate the association between COVID-19 and clinical outcomes among DELIVER participants. Methods and results: Participants with chronic heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) were randomized to dapagliflozin or placebo across 350 sites in 20 countries. COVID-19 was investigator-reported and the contribution of COVID-19 to death was centrally adjudicated. We assessed (i) the incidence of COVID-19, (ii) event rates before/during the pandemic, and (iii) risks of death after COVID-19 diagnosis compared to risks of death in participants without COVID-19. Further, we performed a sensitivity analysis assessing treatment effects of dapagliflozin vs. placebo censored at pandemic onset. Of 6263 participants, 589 (9.4%) developed COVID-19, of whom 307 (52%) required/prolonged hospitalization. A total of 155 deaths (15% of all deaths) were adjudicated as definitely/possibly COVID-19-related. COVID-19 cases and deaths did not differ by randomized assignment. Death rate in the 12 months following diagnosis was 56.1 (95% confidence interval [CI] 48.0–65.6) versus 6.4 (95% CI 6.0–6.8)/100 participant-years among trial participants with versus without COVID-19 (adjusted hazard ratio [aHR] 8.60, 95% CI 7.18–10.30). Risk was highest 0–3 months following diagnosis (153.5, 95% CI 130.3–180.8) and remained elevated at 3–6 months (12.6, 95% CI 6.6–24.3/100 participant-years). After excluding investigator-reported fatal COVID-19 events, all-cause death rates in the 12 months following diagnosis among COVID-19 survivors (n = 458) remained higher (aHR 2.46, 95% CI 1.83–3.33) than rates for all trial participants from randomization, with censoring of participants who developed COVID-19 at the time of diagnosis. Dapagliflozin reduced cardiovascular death/worsening HF events when censoring participants at COVID-19 diagnosis (HR 0.81, 95% CI ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | https://pure.eur.nl/en/publications/9718f2bc-307c-4dce-a0dc-34205e04eeb8Test |
| DOI: | 10.1002/ejhf.3043 |
| الإتاحة: | https://doi.org/10.1002/ejhf.3043Test https://pure.eur.nl/en/publications/9718f2bc-307c-4dce-a0dc-34205e04eeb8Test https://pure.eur.nl/ws/files/115674256/Impact_of_COVID-19_in_patients_with_heart_failure_with_mildly_reduced_or_preserved_ejection_fraction_enrolled_in_the_DELIVER_trial.pdfTest http://www.scopus.com/inward/record.url?scp=85173792619&partnerID=8YFLogxKTest |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.6273B5E7 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1002/ejhf.3043 |
|---|